| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2543817 | Journal of the American Pharmacists Association | 2008 | 5 Pages |
Abstract
This case illustrates a practical use of currently available therapy options to address Lp(a) as a secondary cardiovascular risk factor. Niacin is a preferred option for Lp(a) lowering in very-high-risk patients with coronary heart disease and dyslipidemia. The importance of moderate reductions in Lp(a) is not known.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Daniel M. PharmD, BCPS, Honey E. MD, Heather M. PharmD,